A Phase 3 interventional study of Ecnoglutide Injection and placebo with matching volume in Knee Osteoarthritis and Obesity, sponsored by Hangzhou Sciwind Biosciences Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-31.
Sponsored by Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Osteoarthritis, Knee with a site in China — 32 open to participants now, 32 under way, 4 of them phase 3. Osteoarthritis, Knee · China.
Among the 136 studies in Osteoarthritis, Knee with a site in China, this one is the 17th largest by planned enrollment of the 115 interventional ones that give a count, is one of 12 that started in 2026, is one of 14 in phase 3, reaches primary completion later than 30 of the 31 other live ones, and was the 132nd registered.
3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.
Browse Osteoarthritis, Knee studies →32 of the 136 studies in Osteoarthritis, Knee with a site in China are open now. Recruiting first, the newest first:
China-Japan Friendship Hospital · Sites in China
Ages 18–65
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 18–65
Belief BioMed (Beijing) Co., Ltd · Sites in China
Ages 40–75
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 40–70
Wuxi Cellular Biopharmaceutical Group Ltd. · Sites in China
Ages 40–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 15 · Phase 3 15 · Phase 4 15
First in 2000; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 68 across 2,717 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 100 across the 115 interventional studies, 136 across the 21 observational. Of the 53 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 136 have an industry lead sponsor. The 10 most frequent:
Hangzhou Sciwind Biosciences Co., Ltd. is the lead sponsor of 15 studies on the registry; 7 are open to participants now.
Hangzhou Sciwind Biosciences Co., Ltd. has 1 study filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
9 of the studies in Osteoarthritis, Knee with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06570291Phase 3Wuxi Cellular Biopharmaceutical Group Ltd.Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis | 2026-12 |
| NCT07868224Jiangxi University of Traditional Chinese MedicineValidating Blinding Maintenance of a Sham-Sensitization Control Design for Sensitization Acupuncture Trials | 2026-12-01 |
| NCT07504562ShuGuang HospitalKnee Pain Ejiao Paste for Knee Osteoarthritis | 2026-12-31 |
| NCT06010979Tian HuaClinical Cohort Study of Knee Arthroplasty Assisted by Digital Technology | 2026-12-31 |
| NCT07736352China-Japan Friendship HospitalExploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants. | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 136 studies in Osteoarthritis, Knee with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.
In this Phase III study, eligible participants will be randomized into one of the two cohorts in a 1:1 ratio to receive once-weekly subcutaneous ecnoglutide injection or placebo, including a dose-escalation period, with the total treatment duration of up to 68 weeks, plus 5 weeks of follow-up period. The overall study will last for 73 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Conditions that may interfere with the assessment of target knee pain during screening include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once weekly
Drug: Ecnoglutide Injection
Once weekly
Drug: placebo with matching volume
subcutaneous injection
subcutaneous injection
Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Time frame: Baseline, week 68
Percentage Change in Body Weight
Time frame: Baseline, week 68
Percentage of Participants with ≥5% of Body Weight Loss
Time frame: Baseline, week 68
Percentage of Participants with ≥10% of Body Weight Loss
Time frame: Baseline, week 68
Percentage of Participants with ≥50% of Reduction in WOMAC Pain Subscale Score
Time frame: Baseline, week 68
Change in WOMAC Physical Function Subscale Score
Time frame: Baseline, week 68
Change in Short Form 36 (SF36) V2 Physical Function Subscale Score
Time frame: Baseline, week 68
Absolute Change in Body Weight
Time frame: Baseline, week 68
Percentage of Participants with ≥15% of Body Weight Loss
Time frame: Baseline, week 68
Change in WOMAC Total Score
Time frame: Baseline, week 68
Percentage of Participants with ≥50% of Reduction in WOMAC Physical Function Subscale Score
Time frame: Baseline, week 68
Change in SF36V2 Score
Time frame: Baseline, week 68
Change in PGI-S Pain and Function Score of the Target Knee Joint
PGI-S stands for Patient Global Impressions Scale - Severity
Time frame: Baseline, week 68
Change in PGI-C Pain and Function Score of the Target Knee Joint
PGI-C stands for Patient Global Impressions Scale - Change
Time frame: Baseline, week 68
Change in Body Mass Index (BMI)
Time frame: Baseline, week 68
Change in Walking Distance During the 6-minute Walk Test
Time frame: Baseline, week 68
Percentage of Participants Using Allowed Analgesics During Wash Out
Time frame: Baseline, week 68
Amount of Allowed Analgesics Used During Wash Out
Amount of allowed analgesics used during wash out at end of treatment (week 68)is presented. Allowed analgesic during washout should be taken within 72 hour before the visit and prior to WOMAC assessment.
Time frame: Baseline, week 68
Percentage of Participants Using Analgesics
Time frame: Baseline, week 68
Change in Amount of Analgesics Used
Time frame: Baseline, week 68
Change in Lipid Profile
Include triglicerides, LDL-C, HDL-C, total cholesterol
Time frame: Baseline, week 68
Change in Fasting Plasma Glucose (FPG)
Time frame: Baseline, week 68
Change in HbA1c
Time frame: Baseline, week 68
Change in Fasting Insulin
Time frame: Baseline, week 68
Change in Fasting C-peptide
Time frame: Baseline, week 68
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time frame: Baseline, week 68
Change in Blood Pressure
Time frame: Baseline, week 68
Adverse events
Time frame: Week 1 to week 73 (EOS)
Change in Patient Health Questionnaire-9 (PHQ-9) Score
PHQ-9 questionnaire will be used to monitor status of mental health of the participants.
Time frame: Baseline to week 73 (EOS)
Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS questionnaire will be used to monitor status of mental health of the participants.
Time frame: Baseline to week 73 (EOS)
Change in Waist Circumference
Time frame: Baseline, week 68
Change in Hip Circumference
Time frame: Baseline, week 68
Change in Waist-to-hip Ratio
Time frame: Baseline, week 68
Trough Concentration of Ecnoglutide
Time frame: Week 1 to week 73 (EOS)
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for May 2028, 21 months after the start.
Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 21 months is close to that.
Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ecnoglutide
Hangzhou Sciwind Biosciences Co., Ltd.